As Amvuttra makes inroads in ATTR, Alnylam scraps heart disease trial interim analysis
Oct 27, 2022
1 min read
Readout for newly FDA-approved Amvuttra in a rare heart disease is on many Alnylam investors’ mind. But the company figures patience is a virtue...